Inj, evinacumab-dgnb, 5mg
Products billed under this code include Evkeeza.
Payment limit per 5 MG, by effective quarter, 1Q23 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Evkeeza.
Payment limit per 5 MG, by effective quarter, 1Q23 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Evkeeza | Regeneron Pharmaceuticals, Inc. | 61755-0010-01 | 240 | $48,617.76 |
| Evkeeza | Regeneron Pharmaceuticals, Inc. | 61755-0013-01 | 69 | $13,977.606 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $202.574 | +$4.941 | 5 MG | Inj, evinacumab-dgnb, 5mg | v1, posted September 17, 2026 |
| 3Q26 | $197.633 | $0.00 | 5 MG | Inj, evinacumab-dgnb, 5mg | v1, posted September 15, 2026 |
| 2Q26 | $197.633 | +$0.467 | 5 MG | Inj, evinacumab-dgnb, 5mg | v1, posted September 15, 2026 |
| 1Q26 | $197.166 | +$3.408 | 5 MG | Inj, evinacumab-dgnb, 5mg | v1, posted September 15, 2026 |
| 4Q25 | $193.758 | +$4.006 | 5 MG | Inj, evinacumab-dgnb, 5mg | v1, posted September 8, 2026 |
| 3Q25 | $189.752 | +$3.446 | 5 MG | Inj, evinacumab-dgnb, 5mg | v1, posted March 10, 2026 |
| 2Q25 | $186.306 | $0.00 | 5 MG | Inj, evinacumab-dgnb, 5mg | v1, posted March 10, 2026 |
| 1Q25 | $186.306 | $0.00 | 5 MG | Inj, evinacumab-dgnb, 5mg | v1, posted December 19, 2025 |
| 4Q24 | $186.306 | +$3.651 | 5 MG | Inj, evinacumab-dgnb, 5mg | v1, posted June 11, 2025 |
| 3Q24 | $182.655 | +$3.515 | 5 MG | Inj, evinacumab-dgnb, 5mg | v1, posted June 11, 2025 |
| 2Q24 | $179.14 | $0.00 | 5 MG | Inj, evinacumab-dgnb, 5mg | v1, posted March 11, 2025 |
| 1Q24 | $179.14 | $0.00 | 5 MG | Inj, evinacumab-dgnb, 5mg | v1, posted December 19, 2024 |
| 4Q23 | $179.14 | +$3.363 | 5 MG | Inj, evinacumab-dgnb, 5mg | v1, posted October 10, 2024 |
| 3Q23 | $175.777 | +$3.527 | 5 MG | Inj, evinacumab-dgnb, 5mg | v1, posted June 5, 2024 |
| 2Q23 | $172.25 | $0.00 | 5 MG | Inj, evinacumab-dgnb, 5mg | v1, posted February 23, 2024 |
| 1Q23 | $172.25 | – | 5 MG | Inj, evinacumab-dgnb, 5mg | v1, posted December 6, 2023 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.